Amendments to the Specification:

Please replace the paragraph beginning at page 7, line 5, with following rewritten paragraph:

--Figs. 1A-1D are presentations of empirical data showing the direct interaction between PR-39 peptide and the α7 subunit of proteasomes intracellularly, wherein Fig. 1A recites the amino acid sequence of cloned mouse α7 subunit (SEQ ID NO:7) and Fig. 1B shows the sequence alignment of C-terminal tails of mouse α subunits α1 (SEQ ID NO:8), α2, α3 (SEQ ID NO:9), α4 (SEQ ID NO:10), α5, α6 (SEQ ID NO:11), and α7 (SEQ ID NO:12);--

Please replace the paragraph beginning at page 23, line 15, with following rewritten paragraph:

--As conventionally known and reported [see for example, U.S. Patent No. 5,654,273], the specific peptide can be substituted using conservative substitutions of amino acids having the same or functionally equivalent charge and structure, except for the required amino acid sequence "Arg-Arg-Arg" at the N-terminus and the intermediate amino acid sequences "Pro-Pro-X-X-Pro-Pro-X-X-Pro" (SEQ ID NO:2) and "Pro-Pro-X-X-X-Pro-Pro-X-X-Pro" (SEQ ID NO:3) where X can be substituted freely using any amino acid. Thus, all of the preferred substituted amino acid sequences are of about the same size and each differ from the native PR-39 peptide sequence only by substitutions in the intermediate portions of the structure.--

Please replace the paragraph beginning at page 25, line 1, with following rewritten paragraph:

--Merely as illustrative examples and preferred embodiments of the broad membership constituting this PR-39 derived oligopeptide family, the members comprising 15, 11 and 8 amino acid residues respectively in length are presented below as the PR15, PR11, and PR8 entities respectively. For comparison purposes only, the complete amino acid sequence of the native PR-39 peptide is presented as well.

PR-39:

1 2 3 4 5 6 7 8 9 10 11 12
Arg-Arg-Arg-Pro-Arg-Pro-Pro-Tyr-Leu-Pro-Arg-Pro-

13 14 15 16 17 18 19 20 21 22 23 24
Arg-Pro-Pro-Pro-Phe-Phe-Pro-Pro-Arg-Leu-Pro-Pro-

25 26 27 28 29 30 31 32 33 34 35 36
Arg-Ile-Pro-Pro-Gly-Phe-Pro-Pro-Arg-Phe-Pro-Pro-

37 38 39
Arg-Phe-Pro ~~(SEQ ID NO:2)~~ (SEQ ID NO:1)

PR-15:

1 2 3 4 5 6 7 8 9 10 11 12
Arg-Arg-Arg-Pro-Arg-Pro-Pro-Tyr-Leu-Pro-Arg-Pro-

13 14 15
Arg-Pro-Pro ~~(SEQ ID NO:3)~~ (SEQ ID NO:4)

PR-11:

1 2 3 4 5 6 7 8 9 10 11
Arg-Arg-Arg-Pro-Arg-Pro-Pro-Tyr-Leu-Pro-Arg ~~(SEQ ID NO:4)~~ (SEQ ID NO:5)

PR-8:

1 2 3 4 5 6 7 8
Arg-Arg-Arg-Pro-Arg-Pro-Pro-Tyr ~~(SEQ ID NO:5)~~ (SEQ ID NO:6)--

Please replace the paragraph beginning at page 45, line 2, with following rewritten paragraph:

--To demonstrate the efficiency of shorter-length peptides which collectively are members of the PR-39 derived oligopeptide family in stimulating angiogenesis in-vivo, a novel peptide, PR11, composed of the first 11 amino acid residues [N-terminal end] of the native PR-39 sequence was purposely synthesized. The amino acid sequence of PR11 is as follows:

1 2 3 4 5 6 7 8 9 10 11

Arg-Arg-Arg-Pro-Arg-Pro-Pro-Tyr-Leu-Pro-Arg ~~(SEQ ID NO:7)~~ (SEQ ID NO:5).--